[go: up one dir, main page]

AR103891A1 - Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden - Google Patents

Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden

Info

Publication number
AR103891A1
AR103891A1 ARP160100623A ARP160100623A AR103891A1 AR 103891 A1 AR103891 A1 AR 103891A1 AR P160100623 A ARP160100623 A AR P160100623A AR P160100623 A ARP160100623 A AR P160100623A AR 103891 A1 AR103891 A1 AR 103891A1
Authority
AR
Argentina
Prior art keywords
tslp
protein
manufacture
hospedadora
proteinas
Prior art date
Application number
ARP160100623A
Other languages
English (en)
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR103891A1 publication Critical patent/AR103891A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una proteína de unión a TSLP (linfopoyetina estromal tímica) que comprende: a) CDR1, CDR2 y CDR3 de SEQ ID Nº 9 o una variante de una cualquiera o de todas estas CDR, en la que la variante CDR tiene 1, 2, ó 3 modificaciones de aminoácidos; o b) una secuencia de aminoácidos al menos 90% idéntica a la secuencia de SEQ ID Nº 9; cuya proteína de unión a TSLP tiene una CI₅₀ menor que o igual a 5 nM. Polinucleótidos que codifican dichas proteínas de unión a TSLP, composiciones farmacéuticas y kits que comprenden dichas proteínas de unión a TSLP y a métodos de fabricación. Uso de dichas proteínas de unión a TSLP para fabricar medicamentos para el tratamiento de enfermedades, tal como asma, asociadas con la señalización de TSLP.
ARP160100623A 2015-03-11 2016-03-09 Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden AR103891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562131285P 2015-03-11 2015-03-11

Publications (1)

Publication Number Publication Date
AR103891A1 true AR103891A1 (es) 2017-06-14

Family

ID=55587253

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100623A AR103891A1 (es) 2015-03-11 2016-03-09 Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden

Country Status (13)

Country Link
US (1) US20160264658A1 (es)
EP (1) EP3268032A1 (es)
JP (1) JP2018509153A (es)
KR (1) KR20170123315A (es)
CN (1) CN107428828A (es)
AR (1) AR103891A1 (es)
AU (1) AU2016231122A1 (es)
BR (1) BR112017019412A2 (es)
CA (1) CA2978026A1 (es)
RU (1) RU2017134274A (es)
TW (1) TW201643179A (es)
UY (1) UY36578A (es)
WO (1) WO2016142426A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017123401A1 (en) 2016-01-13 2017-07-20 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
CN106957313B (zh) * 2017-04-08 2018-01-02 山东本源晶体科技有限公司 一种杂多酸晶体的制备方法与用途
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
IL315556A (en) * 2017-08-04 2024-11-01 Regeneron Pharma Methods for treating active eosinophilic esophagitis
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
WO2019204580A1 (en) * 2018-04-20 2019-10-24 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
TW202110882A (zh) 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
MX2022004919A (es) * 2019-12-13 2022-05-16 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anticuerpo anti-linfopoyetina estromal timica (tslp) y sus usos.
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4103235A1 (en) 2020-02-13 2022-12-21 Amgen Inc. Formulations of human anti-tslp antibodies and methods of treating inflammatory disease
EP4103605A1 (en) 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
PE20230115A1 (es) 2020-02-18 2023-01-27 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
US20240190951A1 (en) * 2021-04-23 2024-06-13 Amgen Inc. Anti-tslp antibody compositions and uses thereof
US20240182558A1 (en) * 2021-04-23 2024-06-06 Amgen Inc. Modified anti-tslp antibodies
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
WO2024000303A1 (zh) * 2022-06-29 2024-01-04 晶源生物医药(苏州)有限公司 靶向tslp的重组结合蛋白及其应用
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024163978A2 (en) 2023-02-02 2024-08-08 Medimmune, Llc Treatment of chronic rhinosinusitis with anti-tslp antibody
WO2024186635A2 (en) * 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024238877A1 (en) 2023-05-18 2024-11-21 Medimmune, Llc Treatment of corticosteroid dependent asthma with anti-tslp antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
IN160851B (es) 1982-10-08 1987-08-08 Glaxo Group Ltd
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
NL8601949A (nl) 1985-07-30 1987-02-16 Glaxo Group Ltd Inrichtingen voor het toedienen van medicamenten aan patienten.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
EP1294879B1 (en) * 2000-06-28 2008-12-31 Amgen Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
PT1730676E (pt) 2004-02-16 2013-10-31 Glaxo Group Ltd Contador para utilização com um distribuidor de medicamento
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
BRPI0720271A2 (pt) * 2006-12-14 2014-01-28 Schering Corp Anticorpo anti-tslp projetado
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
TW201018482A (en) * 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2013014208A2 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Antigen binding constructs
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists

Also Published As

Publication number Publication date
UY36578A (es) 2016-09-30
KR20170123315A (ko) 2017-11-07
RU2017134274A (ru) 2019-04-03
TW201643179A (zh) 2016-12-16
US20160264658A1 (en) 2016-09-15
JP2018509153A (ja) 2018-04-05
EP3268032A1 (en) 2018-01-17
BR112017019412A2 (pt) 2018-05-02
WO2016142426A1 (en) 2016-09-15
AU2016231122A1 (en) 2017-09-07
CA2978026A1 (en) 2016-09-15
CN107428828A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
AR103891A1 (es) Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden
AR127371A2 (es) Receptores quiméricos de flt3 y métodos para usarlos
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
BR112019003775A2 (pt) anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
MX2018003827A (es) Anticuerpos anti-cd19 humano con alta afinidad.
MX2021010668A (es) Proteinas de fusion de citoquinas.
IL295534A (en) Improved immunoglobulin variable domains
WO2017218974A3 (en) Treatment of amd using aav2 variant with aflibercept
PH12013502479A1 (en) Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20121184A1 (es) Moleculas de union a dll-4
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
PE20161221A1 (es) Anticuerpos de il-21
EP4406969A3 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
NZ738850A (en) Multivalent and multispecific dr5-binding fusion proteins
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure